Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Does Zoledronic Acid Have Additive Effect on Suppression of Plasma Estrogen Levels ?

  • Published : 2013.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Brufsky A, Harker WG, Beck JT, et al (2007). Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol, 25, 829-36. https://doi.org/10.1200/JCO.2005.05.3744
  2. Eidtmann H, de Boer R, Bundred N, et al (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol, 21, 2188-94. https://doi.org/10.1093/annonc/mdq217
  3. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M (2012). Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol, 30, 2977-80. https://doi.org/10.1200/JCO.2012.42.0273
  4. Gnant M, Mlineritsch B, Luschin-Ebengreuth G (2008). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol, 9, 840-9. https://doi.org/10.1016/S1470-2045(08)70204-3
  5. Gnant M, Mlineritsch B, Schippinger W, et al. (2009). Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med, 360, 679-91. https://doi.org/10.1056/NEJMoa0806285
  6. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al (2007). Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol, 25, 820-8. https://doi.org/10.1200/JCO.2005.02.7102
  7. Kunzmann V, Bauer E, Feurle J, et al (2000). Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood, 96, 384-92.
  8. Pfeiler G, Königsberg R, Fesl C, et al (2011). Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol, 29, 2653-9. https://doi.org/10.1200/JCO.2010.33.2585
  9. Santini D, Vincenzi B, Galluzzo S, et al (2007). Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res, 13, 4482-6. https://doi.org/10.1158/1078-0432.CCR-07-0551
  10. Schech AJ, Nemieboka BE, Brodie AH (2012). Zoledronic acid inhibits aromatase activity and phosphorylation: Potential mechanism for additive zoledronic acid and letrozole drug interaction. J Steroid Biochem Mol Biol, 132, 195-202. https://doi.org/10.1016/j.jsbmb.2012.05.008